FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794426755> ?p ?o ?g. }

• W2794426755 abstract "451 Background: Intermediate endpoints of benefit in metastatic urothelial carcinoma (mUC) nonrandomized trials are necessary to identify promising drugs, particularly for checkpoint inhibitors, where response and progression-free survival remain suboptimal. We previously reported a nomogram (Pond GR et al, 2017 GU Cancers Symposium) using 5 prognostic factors (hemoglobin < 10 g/dL, Eastern Cooperative Oncology Group performance status ≥1, presence of liver metastasis, time from last treatment ≤3 months, and albumin < lower limit of normal) from phase 2 trials of historical agents (eg, taxanes) to estimate 12-month overall survival (OS), against which observed survival could be compared. Nivolumab was granted approval as salvage therapy for patients with mUC, based on the CheckMate (CM) 275 trial; it is thus of interest to compare the nivolumab observed survival versus nomogram-predicted survival results. Methods: Data were obtained from CM 275, including survival and all 5 prognostic factors. Nomogram points were calculated and the expected 12-month OS was estimated. Bootstrap analyses based on 2000 replications were used to estimate 95% confidence intervals (CIs) for the median expected, observed, and difference between the expected and observed 12-month OS values. All tests were 2-sided, with statistical significance defined as P≤0.05. Results: Data were available from 270 patients from CM 275. Fifteen patients did not have albumin recorded and were excluded. Among the 255 evaluable patients, 46 (18.0%) patients had 0 adverse prognostic factors, 85 (33.3%) had 1, and 124 (48.6%) had 2 or more. The observed nivolumab 12-month OS from CM 275 (43.3% [95% CI, 37.0%-50.5%]) was 19.8% higher (95% CI, 13.6%-26.4%) when compared with the nomogram-predicted 12-month OS (23.5%; [95% CI, 22.5%-25.5%]) if patients received historical chemotherapy. Across all 2000 bootstrap samples, the observed nivolumab 12-month OS exceeded the nomogram-predicted 12-month OS. Conclusions: Nivolumab was associated with a significantly improved 12-month OS compared with historical chemotherapy based on the value predicted by the validated nomogram incorporating baseline prognostic factors. Clinical trial information: NCT02387996." @default.
• W2794426755 created "2018-03-29" @default.
• W2794426755 creator A5029344404 @default.
• W2794426755 creator A5047689900 @default.
• W2794426755 creator A5049299646 @default.
• W2794426755 creator A5050435057 @default.
• W2794426755 creator A5052069729 @default.
• W2794426755 creator A5052504518 @default.
• W2794426755 creator A5060579574 @default.
• W2794426755 creator A5063838757 @default.
• W2794426755 creator A5064884168 @default.
• W2794426755 creator A5066094957 @default.
• W2794426755 creator A5068086379 @default.
• W2794426755 creator A5071033599 @default.
• W2794426755 creator A5074756323 @default.
• W2794426755 date "2018-02-20" @default.
• W2794426755 modified "2023-09-30" @default.
• W2794426755 title "Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma." @default.
• W2794426755 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.451" @default.
• W2794426755 hasPublicationYear "2018" @default.
• W2794426755 type Work @default.
• W2794426755 sameAs 2794426755 @default.
• W2794426755 citedByCount "1" @default.
• W2794426755 countsByYear W27944267552018 @default.
• W2794426755 crossrefType "journal-article" @default.
• W2794426755 hasAuthorship W2794426755A5029344404 @default.
• W2794426755 hasAuthorship W2794426755A5047689900 @default.
• W2794426755 hasAuthorship W2794426755A5049299646 @default.
• W2794426755 hasAuthorship W2794426755A5050435057 @default.
• W2794426755 hasAuthorship W2794426755A5052069729 @default.
• W2794426755 hasAuthorship W2794426755A5052504518 @default.
• W2794426755 hasAuthorship W2794426755A5060579574 @default.
• W2794426755 hasAuthorship W2794426755A5063838757 @default.
• W2794426755 hasAuthorship W2794426755A5064884168 @default.
• W2794426755 hasAuthorship W2794426755A5066094957 @default.
• W2794426755 hasAuthorship W2794426755A5068086379 @default.
• W2794426755 hasAuthorship W2794426755A5071033599 @default.
• W2794426755 hasAuthorship W2794426755A5074756323 @default.
• W2794426755 hasConcept C121608353 @default.
• W2794426755 hasConcept C126322002 @default.
• W2794426755 hasConcept C143998085 @default.
• W2794426755 hasConcept C2776694085 @default.
• W2794426755 hasConcept C2777546739 @default.
• W2794426755 hasConcept C2777701055 @default.
• W2794426755 hasConcept C2778342957 @default.
• W2794426755 hasConcept C2780030458 @default.
• W2794426755 hasConcept C2780352672 @default.
• W2794426755 hasConcept C2780775027 @default.
• W2794426755 hasConcept C2911057145 @default.
• W2794426755 hasConcept C3019882237 @default.
• W2794426755 hasConcept C3019894029 @default.
• W2794426755 hasConcept C3020745361 @default.
• W2794426755 hasConcept C34626388 @default.
• W2794426755 hasConcept C71924100 @default.
• W2794426755 hasConceptScore W2794426755C121608353 @default.
• W2794426755 hasConceptScore W2794426755C126322002 @default.
• W2794426755 hasConceptScore W2794426755C143998085 @default.
• W2794426755 hasConceptScore W2794426755C2776694085 @default.
• W2794426755 hasConceptScore W2794426755C2777546739 @default.
• W2794426755 hasConceptScore W2794426755C2777701055 @default.
• W2794426755 hasConceptScore W2794426755C2778342957 @default.
• W2794426755 hasConceptScore W2794426755C2780030458 @default.
• W2794426755 hasConceptScore W2794426755C2780352672 @default.
• W2794426755 hasConceptScore W2794426755C2780775027 @default.
• W2794426755 hasConceptScore W2794426755C2911057145 @default.
• W2794426755 hasConceptScore W2794426755C3019882237 @default.
• W2794426755 hasConceptScore W2794426755C3019894029 @default.
• W2794426755 hasConceptScore W2794426755C3020745361 @default.
• W2794426755 hasConceptScore W2794426755C34626388 @default.
• W2794426755 hasConceptScore W2794426755C71924100 @default.
• W2794426755 hasLocation W27944267551 @default.
• W2794426755 hasOpenAccess W2794426755 @default.
• W2794426755 hasPrimaryLocation W27944267551 @default.
• W2794426755 isParatext "false" @default.
• W2794426755 isRetracted "false" @default.
• W2794426755 magId "2794426755" @default.
• W2794426755 workType "article" @default.